Morphosys AG - ADR

MorphoSys AG operates as a commercial-stage biopharmaceutical company. It uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. The firm also engages in the development and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Novartis

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Tafasitamab sold to Incyte Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cash Shareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024 Novartis provides ample resources to maximize and accelerate pelabresib's potential on a global scale MorphoSys' Management Board and Supervisory Board unanimously support both agreements MorphoSys to host conference call and webcast on Tuesday, February 6, 2024 at 02:00 pm CET (01:00 pm GMT; 08:00 am EST) PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 5, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the company entered into a Business Combination Agreement with Novartis data42 AG and Novartis AG (hereinafter collectively referred to as "Novartis") based on Novartis' intention to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares at an offer price of € 68.00 per share in cash. As part of the Business Combination Agreement with Novartis, Novartis seeks to obtain exclusive, worldwide rights to develop and commercialize pelabresib, an investigational BET inhibitor, and tulmimetostat, an investigational next-generation dual inhibitor of EZH2 and EZH1, across all indications.

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)

Novartis acquires cancer drug developer MorphoSys for $2.9 bln

Basel, February 05, 2024 – Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (FSE: MOR; NASDAQ: MOR), a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. The acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65% of outstanding shares tendered in the takeover offer and regulatory approvals, further expands and complements Novartis pipeline in oncology, one of its priority therapeutic areas, while also enhancing Novartis global footprint in hematology.

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

Deal flow appears to be picking up, particularly in the world of big pharma and biotech stocks. MorphoSys (NASDAQ: MOR ) is the latest company to be reportedly in talks with Novartis (NYSE: NVS ) in a deal that would see its cancer drug portfolio rolled under Novartis' massive umbrella.

Why Is MorphoSys (MOR) Stock Up 50% Today?

Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG , a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter said on Monday.

Exclusive: Novartis in the lead to acquire cancer drug developer MorphoSys-sources

Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69% Anticipated 2024 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Anticipated 2024 OpEx in the range of € 350 to 380 million and 2024 cash burn of approximately € 250 million (excluding debt and interest payments) Preliminary unaudited financial liability from the collaboration with Incyte of approximately € 114 million, representing a reduction of € 112 million MUNICH, GERMANY / ACCESSWIRE / January 30, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary Monjuvi ® (tafasitamab-cxix) U.S. net product sales and gross margin for Monjuvi U.S. net product sales for the full year of 2023 and provides its 2024 financial guidance. In this context, MorphoSys reduces its financial liability from the collaboration with its partner Incyte and credits finance income accordingly.

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

Shares of biotech company MorphoSys have been climbing due to the approval chances of its lead candidate, pelabresib, for the treatment of myelofibrosis. MorphoSys co-markets and sells the drug Monjuvi in the US, which is used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma. Despite some mixed data and intense competition, analysts believe pelabresib could reach peak annual sales of over $1.5 billion, which would significantly increase MorphoSys' valuation and share price.

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P.

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. These findings were presented in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. Myelofibrosis is characteri.

MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

MorphoSys announced positive topline results from its phase 3 trial of pelabresib in frontline myelofibrosis, nearly doubling spleen volume reduction (the primary endpoint) compared to placebo. However, key secondary endpoints assessing symptomatic improvement did not reach statistical significance in the total population. Nevertherless, significant improvement was shown in the pre-specified intermediate-risk subgroup (majority of enrolled patients). Totality of the evidence supports the approval of pelabresib, which could have a significant multi-billion dollar market potential. MorphoSys plans regulatory submissions in the US and Europe in mid 2024.

MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis

Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.

MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study

MorphoSys (NASDAQ: MOR ) stock is falling hard on Tuesday after the company released data from a Phase 3 clinical trial of pelabresib. The study evaluated pelabresib as a treatment for myelofibrosis in combination with ruxolitinib.

Why Is MorphoSys (MOR) Stock Down 20% Today?

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No.

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. MANIFEST-2 met its primary endpoint, as the combination therapy demonstrated a statistically significant and clinically meaningful improvement in.

MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

MorphoSys AG has faced disappointments with some of its programs not performing well in trials and in the market. The company's recent acquisition of Constellation Pharma is seen as a desperate measure by analysts. The upcoming release of topline data for myelofibrosis drug pelabresib could provide a potential positive outcome for MorphoSys.

MorphoSys: Buying Constellation Was A Desperate Measure

MorphoSys reported Q3 2023 earnings with underperformance in Monjuvi sales due to competition and market saturation. There is optimism surrounding the upcoming data readout for Pelabresib, a promising myelofibrosis treatment. The company has a healthy cash runway and potential for market expansion with Pelabresib's success.

MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating)

MorphoSys AG (NASDAQ:MOR ) Q3 2023 Earnings Conference Call November 16, 2023 8:00 AM ET Company Participants Julia Neugebauer - Head of IR Jean-Paul Kress - CEO Tim Demuth - Chief Research and Development Officer Lucinda Crabtree - CFO Conference Call Participants Derek Archila - Wells Fargo Xian Deng - UBS Jason Butler - JMP James Gordon - JP Morgan Philippa Pritchard - Morgan Stanley Manos Mastorakis - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Third Quarter Statement 2023 of MorphoSys.

MorphoSys AG (MOR) Q3 2023 Earnings Call Transcript

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023. “With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis. We look forward to showcasing the topline results of our pivotal MANIFEST-2 study by the end of November and, shortly thereafter, in our detailed oral presentation at ASH 2023,” said Jean-Paul Kress, M.D., Chi.

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 pm GMT; 04:00 pm EST). MorphoSys' Management team will host a conference call and webcast on November 16, 2023, at 02:00 pm CET (01:00 pm GMT; 08:00 am EST) to present the results for the third quarter and first nine months 2023 and provide an outlook for the remainder of the year.

Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event focused on MANIFEST-2 with MorphoSys management and medical experts will be hosted onsite on Monday, December 11 Additional ASH 2023 presentations will highlight new findings from the Phase 2 MANIFEST study of pelabresib and clinical and preclinical studies of tafasitamab PLANEGG and MUNICH GERMANY / ACCESSWIRE / November 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be presented during an oral presentation on Sunday, December 10, at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference is being held in San Diego, California, from December 9 to 12, 2023.

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million) Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65% Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin for Monjuvi U.S. net product sales to be approximately 75% MUNICH, GERMANY / ACCESSWIRE / October 25, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary Monjuvi® U.S. Net Product Sales and Gross Margin for the third quarter of 2023 and provided an update to its financial guidance for 2023. Preliminary Monjuvi® (tafasitamab-cxix) U.S. Net Product Sales are US$ 23.4 million (€ 21.5 million) for the third quarter of 2023 and US$ 67.8 million (€ 62.6 million) for the first nine months of 2023, a 5% and 6% increase from the same periods in 2022, respectively (US$ 22.2 million in Q3 2022 and US$ 64.1 million in the first nine months of 2022).

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

MorphoSys AG's American depositary receipts MOR, +1.38% gained 2% premarket on Wednesday after the biopharma company said its investigational treatment for endometrial cancer was granted fast-track designation by the U.S. Food and Drug Administration. The treatment, tulmimetostat, is designed for patients with advanced, recurrent or metastatic endometrial cancer who have progressed on at least one prior line of treatment.

MorphoSys shares gain as endometrial cancer treatment gets fast-track designation

Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company's third clinical program to receive Fast Track designation PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer harboring AT-rich interacting domain containing protein 1A (ARID1A) mutations and who have progressed on at least one prior line of treatment. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines intended to treat serious conditions and potentially address an unmet medical need, with the goal of getting these important, new therapies to patients earlier.

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys' Q2 2023 earnings exceeded expectations, with Monjuvi sales reaching $23.6m and an operational loss improvement. The company has a solid cash reserve of approximately EUR680m, providing a cash runway for 1-2 years. The upcoming topline data for the pelabresib P3 MANIFEST-2 study is a promising catalyst for stock performance.

News for Morphosys AG - ADR Stock (MOR)